41 Adult & CPC Expedited CR Worksheet

NCI Choose 1
REVIEWER WORKSHEET
Expedited Continuing Review
OMB# 0925-0753, Expiration Date: 07/31/2021

Attachment_B25_Exp_CR

The purpose of the information collection is to conduct reviews of clinical trial studies. NCI guidelines mandate the participation of institutions in the
CIRB for Network group studies. You are being requested to complete this instrument so that we can conduct activities involved with the operations of
the NCI CIRB Initiative. Although your participation in Network group research and completion of the forms is voluntary, if you wish to participate in the
CIRB, you must complete all questions on the form. The information you provide will be combined for all participants and reported as summaries. It will
be kept private to the extent provided by law.
NOTIFICATION TO RESPONDENT OF ESTIMATED BURDEN
Public reporting burden for this collection of information is estimated to average 30 minutes per response, including the time for reviewing instructions,
searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may
not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control
number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this
burden, to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0753). Do not return the
completed form to this address.

STUDY ID:
STUDY TITLE:
PROTOCOL VERSION DATE:
NAME OF CIRB REVIEWER:
ROLE:

Chair

Vice Chair

Designated Reviewer

DATE COMPLETED:
REVIEWER CONFLICT OF INTEREST:
By checking this box, the reviewer confirms there are no conflicts of interest relative to this
study per the Conflict of Interest Policy for CIRB Members.

1.

Indicate the documents reviewed (check all that apply):
NCI Adult/Pediatric CIRB Application for Continuing Review
Study Protocol
CIRB-Approved Consent Form(s)
CIRB-Approved Translated Consent Form(s)
DSMB/Safety Monitoring Committee report
Toxicity Summary
Presentations or publications for the study
Relevant additional information relating to participants’ risks and benefits
Other, please specify

Version 7, 11/20/2015, Updated 07/07/2017

2.

Select the applicable Expedited Review Category below:
Category 8: Continuing Review of research previously approved by the convened CIRB:
(a) where (i) the research is permanently closed to accrual; (ii) all subjects have
completed all research-related interventions; and (iii) the research remains active only
for long term follow-up.
(b) where no subjects have been enrolled and no additional risks have been identified
(Only applicable for CIRB studies that have not been activated by the Cooperative
Group).
(c) where the remaining research activities are limited to data analysis.
Category 9: Continuing Review of research not conducted under an IND or IDE where
category (8) does not apply but the CIRB has determined and documented at a CIRB
meeting that the research involves no greater than minimal risk and no additional risks have
been identified.

3.

4.

Are there any changes in the study’s risks and benefits that change the risk/benefit ratio
and therefore could affect the CIRB’s continuing approval of the study?
Yes (If Yes, stop here. The continuing review will be reviewed at the next convened CIRB
meeting and may be assigned to another reviewer.)
No
In your judgment, do the benefits of this study continue to outweigh the risks?
Yes
No (If No, stop here. The continuing review will be reviewed at the next convened CIRB
meeting and may be assigned to another reviewer.)

5.

Are the following requirements for approval of research satisfied (check the box to verify
the information is present)?
In order to approve research covered by this policy the IRB shall determine that all of the following
requirements are satisfied;
Risks to subjects are minimized: (i) By using procedures which are consistent with sound research design
and which do not unnecessarily expose subjects to risk, and (ii) whenever appropriate, by using procedures
already being performed on the subjects for diagnostic or treatment purposes;
Risks to subjects are reasonable in relation to anticipated benefits, if any, to subjects, and the importance of
the knowledge that may reasonably be expected to result. In evaluating risks and benefits, the IRB should
consider only those risks and benefits that may result from the research (as distinguished from risks and
benefits of therapies subjects would receive even if not participating in the research). The IRB should not
consider possible long-range effects of applying knowledge gained in the research (for example, the
possible effects of the research on public policy) as among those research risks that fall within the purview
of its responsibility;
Selection of subjects is equitable. In making this assessment the IRB should take into account the purposes
of the research and the setting in which the research will be conducted and should be particularly cognizant
of the special problems of research involving vulnerable populations, such as children, prisoners, pregnant
women, mentally disabled persons, or economically or educationally disadvantaged persons;
Informed consent will be sought from each prospective subject or the subject's legally authorized
representative, in accordance with, and to the extent required by §46.116;
Informed consent will be appropriately documented, in accordance with, and to the extent required by
§46.117;
When appropriate, the research plan makes adequate provision for monitoring the data collected to ensure
the safety of subjects;
When appropriate, there are adequate provisions to protect the privacy of subjects and to maintain the
confidentiality of data;

Version 7, 11/20/2015, Updated 07/07/2017

When some or all of the subjects are likely to be vulnerable to coercion or undue influence, such as children,
prisoners, pregnant women, mentally disabled persons, or economically or educationally disadvantaged
persons, additional safeguards have been included in the study to protect the rights and welfare of these
subjects.

6.

Does the current informed consent document(s) accurately reflect information included
in the protocol?
Yes
No (If No, please indicate what information needs to be added:

7.

)

Does the current informed consent document(s) include the following required and
additional elements? (check the box to verify the information is present)
A statement that the study involves research, an explanation of the purposes of the research and the
expected duration of the subject's participation, a description of the procedures to be followed, and
identification of any procedures which are experimental;
A description of any reasonably foreseeable risks or discomforts to the subject;
A description of any benefits to the subject or to others which may reasonably be expected from the
research;
A disclosure of appropriate alternative procedures or courses of treatment, if any, that might be
advantageous to the subject;
A statement describing the extent, if any, to which confidentiality of records identifying the subject will be
maintained;
For research involving more than minimal risk, an explanation as to whether any compensation and an
explanation as to whether any medical treatments are available if injury occurs and, if so, what they consist
of, or where further information may be obtained;
An explanation of whom to contact for answers to pertinent questions about the research and research
subjects' rights, and whom to contact in the event of a research-related injury to the subject; and
A statement that participation is voluntary, refusal to participate will involve no penalty or loss of benefits to
which the subject is otherwise entitled, and the subject may discontinue participation at any time without
penalty or loss of benefits to which the subject is otherwise entitled.
A statement that the particular treatment or procedure may involve risks to the subject (or to the embryo or
fetus, if the subject is or may become pregnant) which are currently unforeseeable;
Anticipated circumstances under which the subject's participation may be terminated by the investigator
without regard to the subject's consent;
Any additional costs to the subject that may result from participation in the research;
The consequences of a subject's decision to withdraw from the research and procedures for orderly
termination of participation by the subject;
A statement that significant new findings developed during the course of the research which may relate to
the subject's willingness to continue participation will be provided to the subject;
The approximate number of subjects involved in the study; and
The following statement for trials activated after 03/12/12: “A description of this clinical trial will be available
on http://www.ClinicalTrials.gov, as required by U.S. Law. This Web site will not include information that can
identify you. At most, the Web site will include a summary of the results. You can search this Web site at any
time.”

8.

Are there any significant new findings that might relate to the participant’s willingness to
continue taking part in the study?
Yes (If Yes, describe what plans are included to notify or re-consent participants and indicate
whether the plans are sufficient:
)

Version 7, 11/20/2015, Updated 07/07/2017

No
9.

Determination:
Approve (complete Approval Period section below)
Approval Period:

One year minus one day (Standard as described by the CIRB
SOPs)
Other
(Provide rationale for less than 1 year in Question
10. Must be approved by the convened CIRB)

Approve Pending Modifications (provide rationale and required modifications in Question
10)
Forward for review by convened CIRB (provide rationale and a description for key
concerns for the CIRB to address in Question 10)
Reviewer requests additional information before a determination can be made (provide
details on additional information required in Question 10)
10.

Comments:

Version 7, 11/20/2015, Updated 07/07/2017